Pipeline

A robust pipeline in pursuit of transformative therapies.

Targeting the root cause of EBV-driven disease

We are working hard to address significant unmet need in cancer and autoimmune diseases with our robust pipeline of investigational T-cell immunotherapies, paving the way for future treatments.

Tabelecleucel (tab-cel®)

Tab-cel® is under investigation for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) and is in earlier stage development for other EBV-associated diseases.

LEARN MORE arrow_forward_ios
  • RR EBV+ PTLD following SOT or HCT
    Phase 3
  • Multi-cohort: EBV+ cancers
    Phase 2

ATA188

We're developing ATA188 as an investigational off-the-shelf, allogeneic T-cell immunotherapy that aims to specifically target EBV-infected B cells and plasma cells for progressive forms of multiple sclerosis (MS).

LEARN MORE arrow_forward_ios
  • Progressive multiple sclerosis (PMS)
    Phase 2

Next-generation CAR T and AlloCAR T programs

Using a molecular toolkit of next-generation technologies, our platform can be modified to develop CAR T and AlloCAR T therapies to target a wide range of non-EBV-associated diseases.

ATA3219

Allogeneic CAR T targeting CD19, currently in clinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.

LEARN MORE arrow_forward_ios
  • ATA3219: B-cell malignancies
    Phase 1

ATA2271/ATA3271

Autologous ATA2271 is in Phase 1 development and allogeneic ATA3271 is in preclinical development: both target solid tumors expressing the tumor antigen mesothelin and leverage novel next-generation 1XX co-stimulatory domain and PD-1 Dominant Negative Receptor technologies.

LEARN MORE arrow_forward_ios
  • ATA2271: Mesothelioma & other solid tumors
    Phase 1
  • ATA3271: Mesothelioma & other solid tumors
    Pre-clinical

Other next-generation AlloCAR T programs

We’re tackling the limitations and challenges of current CAR T therapies by developing novel next-generation allogeneic CAR T approaches.

  • ATA3431: B-cell malignancies
    Pre-clinical
  • Liquid and solid tumor AlloCAR T programs
    Pre-clinical

External Scientific Presentations

December, 2023

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T-cells for the Treatment of B-Cell Malignancies

Download

February 2023

Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing

Download

February 2022

ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors

Download

November 2020

ATA3219: A Potent Next Generation Allogeneic Off the Shelf CD19 CAR T Therapy Without the Need for Gene Editing

Download

November 2020

ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors

Download

June 2020

Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD1 blockade: Translation to a phase I trial

Download

May 2020

Phase 1 Study of the Safety and Efficacy of ATA188, an Off-the-shelf, Allogeneic Epstein-Barr Virus-targeted T-cell Immunotherapy to Treat Progressive Forms of Multiple Sclerosis

Download

April 2019

Functional Demonstration of CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells: An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform

Download

These are investigational agents. Efficacy and safety have not been established.

See what makes our technology unique.